What Re:Cognition Health does

Re:Cognition Health is a specialist cognitive healthcare provider operating 6 UK clinics (London/Harley Street, Birmingham, Bristol, Guildford, Plymouth, Winchester) and 4 US clinics (Fairfax, Chicago, Houston, Fort Worth), with a headcount of 74 employees. The company runs three integrated lines of business: (1) Phase II/III clinical trial services for global pharma and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, Huntington's, migraine, ADHD, autism and MS, generating fees per patient enrolled and randomized; (2) private-pay cognitive healthcare services including the integrated CognitionCheck assessment (combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation for adults aged 50+), administration of FDA-approved amyloid-targeting therapies Leqembi (lecanemab) and Kisunla (donanemab), ADHD and autism assessments, neurology, psychiatry and mental health services, with Medicare reimbursement accepted at US clinics; (3) medico-legal expert witness services in neurology, neuropsychiatry, neuroradiology and neuropsychology for personal injury and clinical negligence law firms, supported by 3T MRI and DTI imaging.

Revenue is generated primarily via per-patient professional services fees from pharmaceutical sponsors, self-pay private patients in the UK, Medicare-covered Alzheimer's infusions in the US, and per-report medico-legal fees from law firms. Go-to-market is hybrid: enterprise business development targeted at pharma/biotech sponsors (including through the PPD Select Partnership Programme with Thermo Fisher Scientific and Global Alzheimer's Platform Foundation membership), direct-to-consumer self-pay with NHS and private medical professional referrals, and sales-led outreach to personal injury solicitors. The company was founded in 2011, expanded to the US in 2018, and is led by co-founder and CEO Dr. Emer MacSweeney. It was the first organization globally to achieve GCSA clinical site certification from IAOCR in both the US and Europe, and is one of the largest providers of amyloid-targeting therapies in Europe.

Name

Re:Cognition Health

Legal name

Re:Cognition Health Limited

Website

https://recognitionhealth.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Re:Cognition Health operates 10 cognitive healthcare clinics across the UK and US, delivering Phase II/III clinical trials for global pharmaceutical sponsors, private-pay cognitive assessments and disease-modifying Alzheimer's treatments (Leqembi, Kisunla), and medico-legal expert witness services in neurology and brain injury.

Ownership category

akta.pro rank

Product category

Neurology and Cognitive Healthcare Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330), Services for the Elderly and Persons with Disabilities (62412)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industries

Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF), Behavioral Health–Integrated Dementia Care Communities (Neuropsychiatric/BPSD Programs) (HLADACAE), Alzheimer’s Specialized Care (Mid/Late-Stage) (HSABAEAC)

Keywords

• Cognitive healthcare services
• Clinical trial site network
• Alzheimer's disease treatment
• Medico-legal expert witness
• Neurological assessment services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Services for Pharma & Biotech Sponsors: Re:Cognition Health earns fees from pharmaceutical and biotech companies (Eli Lilly, AbbVie, ANAVEX, CervoMed, MSD, Sage Therapeutics, Biohaven, Amneal, AC Immune) for conducting Phase II–III clinical trials at their UK and US sites. Revenue is earned per patient enrolled, screened, and randomized, with study durations ranging from 6 weeks to 3 years. The company negotiates centralized contracts and budgets for multi-site UK/US trials.
2. Private Pay Healthcare Services: Revenue from self-pay patients accessing private cognitive health assessments (CognitionCheck), Alzheimer's disease-modifying treatments (Leqembi, Kisunla), ADHD and autism assessments, mental health services, neurology clinics, and therapeutic apheresis. Services are available to UK and international patients at the company's six UK clinic locations. Medicare coverage is accepted for FDA-approved Alzheimer's treatments at US clinics.
3. Medico-Legal Expert Witness Services: Revenue from law firms and barrister chambers for expert witness reports, medical assessments, 3T MRI scans, and court testimony in personal injury and clinical negligence cases involving brain injury, neurological conditions, and cognitive impairment. The company works with leading personal injury law firms on high-value catastrophic injury cases.
4. Medicare Reimbursement (US Clinics): US clinics receive Medicare reimbursement for FDA-approved amyloid-targeting Alzheimer's medications (Leqembi and Kisunla) for early-stage Alzheimer's patients, providing a recurring revenue stream from the federal health insurance program at the company's four US clinic locations.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels10 records

Core offering

Re:Cognition Health operates a network of private cognitive healthcare clinics delivering AI-integrated diagnosis, disease-modifying Alzheimer's treatments (Leqembi and Kisunla), Phase II–III clinical trial site services for pharmaceutical and biotech sponsors, and medico-legal expert witness reports for personal injury and clinical negligence law firms. Its CognitionCheck assessment combines AI cognitive testing, MRI imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation in a single pathway for adults aged 50 and over.

Product overview

Re:Cognition Health is a healthcare company offering a comprehensive portfolio of cognitive healthcare services centered around brain and mind health. The core offerings include CognitionCheck (AI-powered comprehensive cognitive assessment), Alzheimer's treatments (Leqembi and Kisunla), clinical trials for multiple neurological conditions, and private clinics. Additional services span ADHD and autism assessments, mental health services, neurology clinics, medico-legal expert witness services, and advanced imaging technologies including DTI. The company operates across multiple UK locations and four U.S. clinics, combining clinical care with research to advance treatments for Alzheimer's disease and other cognitive conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• CognitionCheck A comprehensive cognitive health assessment for adults aged 50 and over combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation within a single integrated clinical pathway to detect early signs of Alzheimer's disease and cognitive decline.
• Alzheimer's Disease-Modifying Treatments (Leqembi and Kisunla) Private administration of monoclonal antibody therapies (Leqembi/lecanemab and Kisunla/donanemab) that target and clear amyloid-beta plaques in the brain to slow cognitive decline in early-stage Alzheimer's disease, with Medicare coverage for FDA-approved medications at US clinics.
• Clinical Trials (Phase II–III Site Services) Phase II–III clinical trial site services for pharmaceutical and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, ADHD, Migraine, Autism, and Multiple Sclerosis, including rapid study start-up, centralized UK/US contracting, and budget negotiation.
• Medico-Legal Expert Witness Services Expert witness reports and medical assessments in neurology, neuropsychiatry, neuroradiology, and neuropsychology for personal injury and clinical negligence cases involving brain injury, supported by 3T MRI and DTI imaging, with capacity assessments and court testimony.
• Private Cognitive Healthcare Clinics

Quantifiable outcome

• Kisunla (donanemab) slowed cognitive decline by 35% in total study population over 18 months, up to 60% in MCI participants, and reduced loss of daily function by 40%. One-third of patients achieved amyloid clearance by 6 months.
• +5 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• CeracoreStrategic or Co-development Partner · 20 February 2026Re:Cognition Health and Cera partnered in February 2026 to improve access to Alzheimer's Disease and neurodegenerative clinical trials by linking home care with specialist research centres. The collaboration aims to facilitate early referral, assessment, and trial participation for patients who are currently difficult to reach through traditional clinic-based methods. Home healthcare visits enable screening and monitoring that would otherwise require clinic visits, expanding the reach of clinical trials to housebound or mobility-limited patients.
• Re:Cognition Health Brain and Mind FoundationsupportingOthers · 1 December 2025The Brain and Mind Foundation was launched by Re:Cognition Health in December 2025 to drive meaningful change, fund hope, and improve lives for those affected by neurological conditions. The Foundation harnesses the company's trans-Atlantic clinical expertise to fund breakthrough research, advance earlier diagnosis, and champion adoption of new biomarkers. It operates as a fundraising and research funding vehicle engaging donors, partners, and the wider community.
• Scan.comsupportingTechnology or Integration · 1 June 2025Re:Cognition Health partnered with Scan.com to provide MRI imaging access to patients nationwide through a network of more than 300 imaging centres across the UK. This partnership makes CognitionCheck assessments geographically accessible to patients regardless of their proximity to company clinic locations, extending the reach of the company's diagnostic services across the entire UK.
• Thermo Fisher Scientific (PPD Clinical Research)coreStrategic or Co-development Partner · 1 August 2024Re:Cognition Health UK and US site networks are preferred sites within the PPD Select Partnership Programme of Thermo Fisher Scientific's PPD clinical research business, a global leader in clinical research. The relationship provides preferential access to clinical trial opportunities and strategic site collaborations across the company's 10 existing sites. This is described as an exciting relationship bringing significant opportunities for the company's clinical trial operations.
• Global Alzheimer's Platform (GAP) FoundationcoreStrategic or Co-development Partner · 1 June 2018Re:Cognition Health is the only non-US/Canadian member of the Global Alzheimer's Platform Foundation, a patient-centric nonprofit dedicated to speeding the delivery of innovative Alzheimer's therapies by reducing the time and cost of clinical trials. This membership provides access to a global network of research sites and pharma partnerships, and positions the company as a preferred global partner for Alzheimer's clinical research.
• Inova Memory Center, Inova Fairfax HospitalcoreStrategic or Co-development Partner · 1 June 2018The first US clinic (Fairfax, Virginia) operates in partnership with Inova Memory Center at Inova Fairfax Hospital. Dr. James Bicksel, Neurologist and Medical Director of Inova Memory Center, serves as Principal Investigator at the US site. The Inova Memory Center is a leading memory programme in the Washington D.C. area, adding clinical credibility and referral pathways to the company's US operations.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Cambridge Cognition: UK-based provider of digital cognitive assessment technologies used in clinical trials and healthcare. Highly comparable because both companies deliver cognitive testing to pharma trial sponsors and run proprietary assessment platforms (CognitionCheck vs CANTAB).
• MAC Clinical Research: UK-based clinical trial site network operating dedicated early and late-phase research clinics. Directly comparable to Re:Cognition Health's UK trial operations — both are private UK site networks running multi-therapeutic Phase II–III studies for global pharma sponsors.
• Cogstate: Australia/US-based provider of computerized cognitive testing for clinical trials, healthcare, and academic research. Comparable to Re:Cognition Health as both monetize cognitive assessment in pharma-sponsored trials and neurodegenerative drug development.
• Richmond Pharmacology: UK clinical research organization specializing in early-phase clinical trials, including CNS studies. Comparable because it operates UK-based clinical trial infrastructure serving global pharma — similar customer base and regulatory complexity to Re:Cognition Health's trial services.
• Compass Pathways: UK-headquartered mental health clinical-stage company running psychedelic therapy clinical trials for treatment-resistant depression. Comparable because both operate UK-based specialist clinical research operations for CNS indications targeting a similar regulatory and patient-recruitment environment.

Emerging players

• Alto Neuroscience: Clinical-stage neuroscience company using biomarkers to develop precision psychiatry therapeutics and running trials in depression and ADHD. Comparable emerging overlap with Re:Cognition Health's adult ADHD assessment and psychiatry services for CNS drug development.

Others

• Cerveau Technologies: Provider of tau PET imaging ligands used in Alzheimer's disease clinical research. Comparable as an adjacent enabling partner in the same Alzheimer's biomarker ecosystem that Re:Cognition Health's CognitionCheck and clinical trial business operates within.

Broad incumbents

• Clario: Global clinical trial technology and imaging company (formed via merger of Bioclinica and ERT) supporting CNS trials with imaging, eCOA, and biomarker solutions. Comparable as a broad incumbent serving the same pharma sponsors on neurodegenerative trials that Re:Cognition Health runs as a site.
• IXICO: UK-listed neuroimaging analytics company providing imaging biomarkers and AI tools for neurodegenerative clinical trials. Comparable to Re:Cognition Health's DTI/3T MRI and CognitionCheck imaging components, but operates as a technology vendor rather than a clinic operator.

Regional players

• Inova Memory Center: US-based memory disorders clinical and research program operated within Inova Fairfax Hospital. Comparable to Re:Cognition Health's Fairfax US site as both deliver specialist Alzheimer's and memory-disorder diagnosis, treatment, and clinical trial participation in the Washington DC metropolitan area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/results?search_query=TEDxAthens+Emer+MacSweeney
• Instagraminstagram.com/recognitionhealth
• Xx.com/recoghealth

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Re:Cognition Health